)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Lyell Immunopharma (LYEL) investor relations material
Lyell Immunopharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Advanced pivotal trials for lead CAR T-cell therapy (ronde-cel) in large B-cell lymphoma, with strong response rates in both 2L and 3L+ settings and manageable safety profile; received RMAT designation from the FDA for both settings.
Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell candidate for metastatic colorectal cancer, showing a 67% overall response rate and 83% disease control rate at the highest dose in a U.S. Phase 1 trial.
Transitioned manufacturing to the LyFE facility, supporting clinical and early commercial supply.
Raised $50M in equity financing and secured options for an additional $50M, strengthening liquidity.
Cash position of $319.6M–$320M at quarter-end, expected to fund operations into 2027 through key milestones.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $319.6M–$320M as of September 30, 2025, down from $384M at year-end 2024.
Net loss for Q3 2025 was $38.8M (GAAP), improved from $44.6M in Q3 2024; non-GAAP net loss was $29.1M for Q3 2025.
Research and development expenses decreased to $28.2M (GAAP) and $26.2M (Non-GAAP) in Q3 2025 from $39.5M in Q3 2024.
General and administrative expenses were $10.7M (GAAP) and $7.5M (Non-GAAP) in Q3 2025, both lower year-over-year.
Operating cash outflow was $117.8M for the nine months ended September 30, 2025.
Outlook and guidance
Existing cash resources expected to fund operations into 2027 and support advancement of the pipeline through key clinical milestones.
Anticipates additional capital needs for late-stage development and commercialization.
Plans to present updated pivotal trial data at ASH in December 2025 and submit a BLA for ronde-cel in 2027.
First patient enrollment in the PiNACLE-H2H Phase 3 trial expected by early 2026; next LYL273 Phase 1 data update anticipated in H1 2026.
IND submission for a new solid tumor CAR T-cell candidate expected in 2026.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Lyell Immunopharma earnings date
Q4 202510 Mar, 2026
Next Lyell Immunopharma earnings date
Q4 202510 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Lyell Immunopharma Inc is a biotechnology company focused on developing cell-based immunotherapies for cancer treatment. The company specializes in genetically engineering T cells to enhance their persistence, potency, and functionality against solid tumors. Lyell Immunopharma conducts research and development activities in collaboration with academic and industry partners. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage